α 1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α 1-antitrypsin deficiency: Number and costs of years of life gained

Clinical Drug Investigation

Volumn 32, Issue 5, 2012, Pages 353-360

  Sclar, David Alexander ^a   Evans, Marc A ^a   Robison, Linda M ^a   Skaer, Tracy L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

1 antitrypsin deficiency; cost benefit; lung transplantation; mortality

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DECISION THEORY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEREDITARY EMPHYSEMA; HUMAN; LIFE EXPECTANCY; LUNG EMPHYSEMA; LUNG INFECTION; LUNG TRANSPLANTATION; MALE; MONTE CARLO METHOD; MORTALITY; PRIORITY JOURNAL; PROBABILITY; SMOKING; STOCHASTIC MODEL;

ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; COST OF ILLNESS; DECISION SUPPORT TECHNIQUES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MONTE CARLO METHOD; PULMONARY EMPHYSEMA; RISK FACTORS; SEX FACTORS; SMOKING; YOUNG ADULT;

EID: 84859787234     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11631920-000000000-00000     Document Type: Article

References (32)

1. Abboud RT, Ford GT, Chapman KR, et al., for the Standards Committee of the Canadian Thoracic Society. Alpha1- antitrypsin deficiency: A position statement of the Canadian Thoracic Society. Can Respir J 2001; 8 (2): 81-88 (Pubitemid 32496355)
2. Cox DW, Woo SLC, Mansfield T. DNA restriction fragments associated with alpha 1-Antitrypsin indicate a single origin for deficiency allele PIZ. Nature 1985; 316: 79-81 (Pubitemid 15013719)
3. Cox DW, Billingsley GD, Mansfield T. DNA restriction site polymorphisms associated with the alpha 1-Antitrypsin gene. Am J Hum Genet 1987; 41: 891-906
4. Sveger T. Alpha1-Antitrypsin deficiency in early childhood. Pediatrics 1978; 62: 22-5
5. O'Brien ML, Buist NRM, Murphey WH. Neonatal screening for alpha 1-Antitrypsin deficiency. J Pediatr 1978; 92: 1006-10 (Pubitemid 8327375)
6. Silverman EK, Miletich SP, Pierce JH, et al. Alpha-1-Antitrypsin deficiency: High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989; 140: 961-966 (Pubitemid 19259496)
7. Colp C, Pappas J, Moran D, et al. Variants of alpha 1-Antitrypsin in Puerto Rican children with asthma. Chest 1993; 103: 812-815 (Pubitemid 23086180)
8. Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha-1-Antitrypsin. Am J Respir Crit Care Med 1998; 158: 49-59
9. Larsson C. Natural history and life expectancy in severe alpha 1-Antitrypsin deficiency, PiZ. Acta Med Scand 1978; 204: 345-51 (Pubitemid 9051719)
10. Stoller JK, Smith P, Yank P, et al. Physical and social impact of alpha 1-Antitrypsin deficiency: Results of a survey. Cleveland Clinic J Med 1994; 61: 461-467
11. Seersholm N, Kok-Jensen A, Dirksen A. Decline in FEV1 among patients with severe hereditary alpha 1-Antitrypsin deficiency type PiZ. Am J Respir Crit Care Med 1995; 152: 1922-5
12. Tobin MJ, Cook PJL, Hutchison DCS. Alpha 1 antitrypsin deficiency: The clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. Br J Dis Chest 1983; 77: 14-27 (Pubitemid 13183041)
13. McElVaney NG, Stoller JK, Buist AS, et al., Alpha 1-Antitrypsin Deficiency Study Group. Baseline characteristics of enrollees in the National Heart, Lung, and Blood Institute Registry of Alpha 1-Antitrypsin Deficiency. Chest 1997; 111: 394-403 (Pubitemid 27096957)
14. Hutchinson DCS. Natural history of alpha-1-protease inhibitory deficiency. Am J Med 1988; 84 Suppl. 6A: 3-12
15. Buist AS, Burrows B, Eriksson S, et al. The natural history of air-flow obstruction in PiZ emphysema. Am Rev Respir Dis 1982; 127: S43-50
16. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma a1-Antitrypsin. Chest 2002; 122: 66-74 (Pubitemid 34754144)
17. Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-Antitrypsin deficiency. JAMA 1988; 260: 1259-64
18. Fishman GS. Monte Carlo: concepts, algorithms, and applications. Springer Series in Operations Research. New York (NY): Springer-Verlag, 1996
19. Robert CP, Casella G. Monte Carlo statistical methods. Springer Texts in Statistics. New York (NY): Springer- Verlag, 1999
20. U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Examination Data File (CD ROM). Public Use Data File Documentation Number 76200. Hyattsville (MD): Centers for Disease Control and Prevention, 1996
21. Mullins CD, Huang Z, Merchant S, et al. The direct medical cost of alpha(1)-Antitrypsin deficiency. Chest 2001; 119: 745-52 (Pubitemid 32197643)
22. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Disease 1981; 123: 659-64 (Pubitemid 11117589)
23. Wencker M, Fuhrmann B, Banik N, et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119: 737-44 (Pubitemid 32197642)
24. Hosenpud JD, Novick RJ, Breen TJ, et al. The Registry of the International Society for Heart and Lung Transplantation: Twelfth official report. J Heart Lung Transplant 1995; 14: 805-15
25. Levine SM, Anzueto A, Peters JI, et al. Medium term functional results of single-lung transplantation for end stage obstructive lung disease. Am J Respir Crit Care Med 1994; 150: 398-402 (Pubitemid 24252350)
26. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: A new hypothesis with supporting data. Chest 2000; 118: 1480-5
27. American Thoracic Society/European Respiratory Society statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818-900
28. Gildea TR, Shermock KM, Singer ME, et al. Costeffectiveness analysis of augmentation therapy for severe alpha1-Antitrypsin deficiency. Am J Respir Crit Care Med 2003; 167: 1387-92 (Pubitemid 36609724)
29. Alkins SA, O'Malley P. Should health-care systems pay for replacement therapy in patients with alpha(1)-Antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest 2000; 117: 875-80 (Pubitemid 30152232)
30. Mullins CD, Wang J, Stoller JK. Major components of the direct medical costs of alpha1-Antitrypsin deficiency. Chest 2003; 124: 826-31 (Pubitemid 37123296)
31. Troche CJ, Tacke J, Hinzpeter B, et al. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur Heart J 1998; 19 Suppl. C: C59-65 (Pubitemid 28171860)
32. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997; 127: 955-65